Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279200 | 0.85 | SYK (0.39) | ADORA2AADORA1SYK | |
| SCHEMBL1118241 | 0.84 | MALT1 (0.45) | MAP4K1 | |
| SCHEMBL19670056 | 0.79 | ADORA2A (0.33) | ADORA2AADORA1SYK | |
| SCHEMBL2625468 | 0.79 | ADRB1 (0.41) | SYK | |
| SCHEMBL27269565 | 0.79 | ADORA2A (0.33) | ADORA2AADORA1SYK | |
| SCHEMBL12553829 | 0.79 | IDH1 (0.33) | ADORA2AADORA1SYK | |
| SCHEMBL18532095 | 0.76 | ADORA2A (0.34) | ADORA2AADORA1 | |
| SCHEMBL17816271 | 0.75 | JAK2 (0.42) | ADORA2AADORA1 | |
| SCHEMBL1828405 | 0.74 | NOS3 (0.37) | ADORA2AADORA1NUDT1 | |
| SCHEMBL24349548 | 0.73 | HMGCR (0.33) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | ADORA2A 330/4885ADORA1 575/4885NUDT1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.